Ajovy Dosing and Administration: Complete Guide for Healthcare Providers

Ajovy (fremanezumab-vfrm) is a CGRP antagonist monoclonal antibody approved for the preventive treatment of migraine in adults. The medication is administered as a subcutaneous injection and is available in prefilled syringes for patient self-administration or healthcare provider administration.

The recommended dosing for Ajovy offers flexibility with two approved regimens. Patients may receive either 225 mg administered monthly as a single subcutaneous injection, or 675 mg administered quarterly (every 3 months) as three consecutive subcutaneous injections. Both dosing schedules have demonstrated comparable efficacy in clinical trials for migraine prevention.

Ajovy should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) and protected from light. Prior to injection, the medication should be removed from refrigeration and allowed to reach room temperature for approximately 30 minutes. The injection sites should be rotated and include the thigh, abdomen, or upper arm, avoiding areas that are tender, bruised, or scarred.

Healthcare providers should educate patients on proper injection technique and site rotation when prescribing Ajovy for self-administration. The medication's flexible dosing schedule may improve adherence compared to more frequent dosing regimens. Patients should be monitored for injection site reactions and overall treatment response during follow-up visits.